-transparent.png){kind=logo}
Twenty-two oophorectomized or postmenopausal women with metastatic breast cancer resistant to several medical therapies (tamoxifen, or other endocrine therapy, and chemotherapy) were treated in a first trial with 200 mg per day of RU486 for 1 to 3 months. The long-term tolerance was good but there was a moderate decrease in plasma potassium. Plasma cortisol was increased 2-fold without clinical hypo- or hypercorticism. Twelve patients had a partial response or a stabilization of secondary deposits for 6 weeks but the response rate at 3 months was 18%. When available, estrogen and progesterone receptor levels were positive in these patients. This preliminary trial shows for the first time that the antiprogestin RU486 is well tolerated for medium term treatment. It suggests that it might be active on advanced breast cancer becoming resistant to tamoxifen.
G Romieu, and
T Maudelonde, and
A Ulmann, and
H Pujol, and
J Grenier, and
G Cavalie, and
S Khalaf, and
H Rochefort
October 1987,
Breast cancer research and treatment,
G Romieu, and
T Maudelonde, and
A Ulmann, and
H Pujol, and
J Grenier, and
G Cavalie, and
S Khalaf, and
H Rochefort
January 1991,
Reproduction, fertility, and development,
G Romieu, and
T Maudelonde, and
A Ulmann, and
H Pujol, and
J Grenier, and
G Cavalie, and
S Khalaf, and
H Rochefort
November 1987,
Journal of steroid biochemistry,
G Romieu, and
T Maudelonde, and
A Ulmann, and
H Pujol, and
J Grenier, and
G Cavalie, and
S Khalaf, and
H Rochefort
August 1987,
Fertility and sterility,
G Romieu, and
T Maudelonde, and
A Ulmann, and
H Pujol, and
J Grenier, and
G Cavalie, and
S Khalaf, and
H Rochefort
August 1990,
Journal of steroid biochemistry,
G Romieu, and
T Maudelonde, and
A Ulmann, and
H Pujol, and
J Grenier, and
G Cavalie, and
S Khalaf, and
H Rochefort
November 1974,
European journal of cancer,
G Romieu, and
T Maudelonde, and
A Ulmann, and
H Pujol, and
J Grenier, and
G Cavalie, and
S Khalaf, and
H Rochefort
January 1978,
Medical and pediatric oncology,
G Romieu, and
T Maudelonde, and
A Ulmann, and
H Pujol, and
J Grenier, and
G Cavalie, and
S Khalaf, and
H Rochefort
March 2017,
Hormones and behavior,
G Romieu, and
T Maudelonde, and
A Ulmann, and
H Pujol, and
J Grenier, and
G Cavalie, and
S Khalaf, and
H Rochefort
April 1974,
Cancer,
G Romieu, and
T Maudelonde, and
A Ulmann, and
H Pujol, and
J Grenier, and
G Cavalie, and
S Khalaf, and
H Rochefort
January 1990,
Journal of obstetrics and gynaecology,
